Format

Send to

Choose Destination
Ther Adv Med Oncol. 2015 Mar;7(2):85-96. doi: 10.1177/1758834014567470.

Nivolumab in NSCLC: latest evidence and clinical potential.

Author information

1
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
2
Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea.
3
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA.
4
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, 1E Kent Ridge Road, NUHS Tower Block Level 7, Singapore 119228.

Abstract

New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

KEYWORDS:

immune checkpoint modulator; nivolumab; non-small cell lung cancer; programmed death-1; programmed death-1 ligand

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center